GLP1R and pneumonia: The incidence of 12 types of respiratory diseases was evaluated, although their incidence was overall very low, the lowest for interstitial lung disease (0.02% in the GLP-1 receptor agonist group and 0.04% in the control group) and the highest for pneumonia (2.05% in the GLP-1 receptor agonist group and 2.31% in the placebo group).